mutLBSgeneDB |
Gene summary for GDF2 |
Gene summary |
Basic gene Info. | Gene symbol | GDF2 |
Gene name | growth differentiation factor 2 | |
Synonyms | BMP-9|BMP9|HHT5 | |
Cytomap | UCSC genome browser: 10q11.22 | |
Type of gene | protein-coding | |
RefGenes | NM_016204.2, | |
Description | GDF-2bone morphogenetic protein 9growth/differentiation factor 2 | |
Modification date | 20141219 | |
dbXrefs | MIM : 605120 | |
HGNC : HGNC | ||
Ensembl : ENSG00000263761 | ||
HPRD : 05492 | ||
Vega : OTTHUMG00000188320 | ||
Protein | UniProt: Q9UK05 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_GDF2 | |
BioGPS: 2658 | ||
Pathway | NCI Pathway Interaction Database: GDF2 | |
KEGG: GDF2 | ||
REACTOME: GDF2 | ||
Pathway Commons: GDF2 | ||
Context | iHOP: GDF2 | |
ligand binding site mutation search in PubMed: GDF2 | ||
UCL Cancer Institute: GDF2 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0001569 | patterning of blood vessels | 20406889 | GO:0001937 | negative regulation of endothelial cell proliferation | 20406889 | GO:0001938 | positive regulation of endothelial cell proliferation | 20406889 | GO:0010596 | negative regulation of endothelial cell migration | 17068149 | GO:0010862 | positive regulation of pathway-restricted SMAD protein phosphorylation | 17068149 | GO:0030308 | negative regulation of cell growth | 17068149 | GO:0030509 | BMP signaling pathway | 17068149 | GO:0032757 | positive regulation of interleukin-8 production | 19366699 | GO:0032924 | activin receptor signaling pathway | 17068149 | GO:0045766 | positive regulation of angiogenesis | 20406889 | GO:0045893 | positive regulation of transcription, DNA-templated | 17068149 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 19366699 | GO:0048514 | blood vessel morphogenesis | 20406889 | GO:0060389 | pathway-restricted SMAD protein phosphorylation | 17068149 | GO:0071773 | cellular response to BMP stimulus | 19366699 | GO:2000279 | negative regulation of DNA biosynthetic process | 19366699 |
Top |
Ligand binding site mutations for GDF2 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | H381 | K383N | BRCA | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for GDF2 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | H381 | K383N | -1.1637763 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for GDF2 from PDB |
Top |
Differential gene expression and gene-gene network for GDF2 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for GDF2 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C2239176 | Carcinoma, Hepatocellular | 2 | Biomarker |
umls:C3809710 | TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5 | 1 | GeneticVariation |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for GDF2 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of GDF2 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
Top |
Conservation information for LBS of GDF2 |
Multiple alignments for Q9UK05 in multiple species |
LBS | AA sequence | # species | Species | H381 | VQTLVHLKFPT | 2 | Homo sapiens, Mus musculus | H381 | VQTLVHLQNPK | 1 | Gallus gallus | K390 | PTKVGKACCVP | 2 | Homo sapiens, Mus musculus | K390 | PKKASKACCVP | 1 | Gallus gallus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |